Valeant just got a new weapon in its battle with AstraZeneca for the opioid-induced constipation throne. But don't expect oral Relistor to power that…

What’s in a new name? For a Takeda and Lundbeck antidepressant, new marketing work.

Tenet Partners is out with its ninth annual evaluation of the most powerful brands, and a pair of pharmas locked up top spots on the list.

Pharma marketers may have felt reprieved after a former Warner Chilcott sales chief was acquitted last month. But now, two former Johnson & Johnson execs…

AstraZeneca may so far be on the outside looking in with its DPP-4/SGLT2 combo when it comes to the U.S. market. On its home continent, though, it now has a…

The Crestor generics are coming. AstraZeneca failed its last-ditch attempt to protect the blockbuster brand Tuesday, when a federal judge denied its bid for a…

Golf outings at top courses. Box suites at sporting events. A Los Angeles Lakers basketball camp. And the usual “lavish dinners.” They all figured into a $30…

An offhand Novartis disclosure Tuesday showed that Amgen scored a break on biosimilars: The FDA rejected Novartis' biosim version of the Big Biotech'…

Novartis sales held steady despite new Gleevec generics, and the Swiss drugmaker is optimistic enough about new meds to sink more money into marketing and…